PARIS, Oct 19 (Reuters) - Laboratory testing and diagnostics company Eurofins said its new at-home COVID nasal testing product had received 'Emergency Use Approval' (EUA) status from the U.S. Food & Drug Administration regulatory body.

Eurofins said the EUA authorised self-collection kit gives consumers a convenient and quick option to test from the comfort of their home, with results reviewed by a licensed physician and provided via email within 24 hours of sample receipt.

Worldwide coronavirus cases crossed 40 million on Monday, according to a Reuters tally, as the onset of winter in the northern hemisphere fuelled a resurgence in the spread of the disease. (Reporting by Sudip Kar-Gupta; Editing by Muralikumar Anantharaman)